In this video interview, Sujay Jadhav, CEO of Verana Health, highlights how the industry can use RWD to compare outcomes from treatment and non-treatment arms. In a recent video interview with Applied ...

In this video interview, Sujay Jadhav, CEO of Verana Health, discusses how the use of unstructured data can help improve clinical research in 2025. In a recent video interview with Applied Clinical ...

Results from the Phase III MARIPOSA trial demonstrated the combination of Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) significantly improves overall survival compared to the current ...

The annual SCOPE (Summit for Clinical Operations Executives) conference has revealed the six finalists for its 9 th Annual Participant Engagement Award. This prestigious award recognizes advancements ...

Initial data from Phase I clinical trial showed encouraging single agent activity in patients with different types of PD-1 resistant tumors. The FDA has granted Fast Track designation to Marengo ...

The FDA announced it has issued a new draft guidance on the use of artificial intelligence (AI) in supporting regulatory decision-making on a drug or biological product’s safety, effectiveness, or ...

In this video interview, Sujay Jadhav, CEO of Verana Health, discusses how using genomic data and real-world evidence can provide added context to traditional factors such as Gleason scores and PSA ...

In this video interview, Sujay Jadhav, CEO of Verana Health, talks AI and its role in optimizing trial design. In a recent video interview with Applied Clinical Trials, Sujay Jadhav, CEO of Verana ...

Over the past two years, generative artificial intelligence (AI) has emerged as a top strategic priority in the life sciences industry, driving innovation across drug development and regulatory ...

In this video interview, Rachael Fones, director, government & public affairs, IQVIA, discusses some of the key ways that different trial sponsors may need support in meeting diversity expectations.

Phase III trial shows the combination of brexpiprazole plus sertraline significantly improved the symptoms of post-traumatic stress disorder compared to sertraline plus placebo, with a tolerable ...

A Phase Ib/II dose escalation and expansion trial shows promising antitumor activity and durable responses with Talvey (talquetamab) plus Tecvayli (teclistamab) in the treatment of relapsed or ...